文献速递骨软组织肉瘤与黑色素瘤

达拉非尼联合曲美替尼辅助治疗BRAFV600E或BRAFV600K突变高危黑色素瘤切除术后患者的患者报告结局(COMBI-AD):一项随机、安慰剂对照的3期试验

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2019-03-27

COMBI-AD研究纳入870例完全切除的III期BRAFV600E或BRAFV600K突变黑色素瘤患者,随机接受达拉非尼联合曲美替尼或安慰剂治疗12个月。治疗期间及长期随访中,两组EQ-5D-3L视觉模拟量表(VAS)和效用评分均无显著或临床有意义的差异;复发时两组VAS和效用评分均显著下降。

要点

  • 治疗期间两组EQ-VAS和效用评分较基线无显著或临床有意义的差异。
  • 长期随访中两组VAS和效用评分相似,且与基线无差异。
  • 复发时两组VAS和效用评分均显著下降。

核心结论

  • 达拉非尼联合曲美替尼在辅助治疗期间及之后未影响患者报告结局评分,提示通过辅助治疗预防或延迟复发可能获益。

研究设计与样本

  • COMBI-AD为随机、双盲、安慰剂对照3期研究,在25个国家169个中心开展。
  • 纳入870例完全切除的III期(AJCC第7版IIIA、IIIB或IIIC)BRAFV600E或BRAFV600K突变皮肤黑色素瘤患者,ECOG体能状态0或1。
  • 按1:1随机接受口服达拉非尼150 mg每日两次联合口服曲美替尼2 mg每日一次或匹配安慰剂治疗12个月。
  • 主要终点为无复发生存,健康相关生活质量为预设探索性终点,采用EQ-5D-3L问卷在意向治疗人群中评估。

主要发现

  • 2013年1月31日至2014年12月11日入组870例,达拉非尼联合曲美替尼组438例,安慰剂组432例。
  • 达拉非尼联合曲美替尼组中位随访34个月(IQR 28-39),安慰剂组33个月(IQR 20.5-39)。
  • 12个月治疗期间,两组EQ-VAS和效用评分较基线无显著或临床有意义的改变。
  • 治疗期间,达拉非尼联合曲美替尼组中发生与未发生最常见不良事件的患者间VAS和效用评分无临床有意义差异。
  • 长期随访(范围15-48个月)中,两组VAS和效用评分相似,且与基线无差异。

临床怎么用

  • 作者认为,这些发现提示通过辅助治疗预防或延迟复发可能获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the phase 3 COMBI-AD study, patients with resected, stage III melanoma with BRAFV600E or BRAFV600K mutations received adjuvant dabrafenib plus trametinib or placebo. The primary analysis showed that dabrafenib plus trametinib significantly improved relapse-free survival at 3 years. These results led to US Food and Drug Administration approval of dabrafenib plus trametinib as adjuvant treatment for patients with resected stage III melanoma with BRAFV600E or BRAFV600K mutations. Here, we report the patient-reported outcomes from COMBI-AD. METHODS: COMBI-AD was a randomised, double-blind, placebo-controlled, phase 3 study done at 169 sites in 25 countries. Study participants were aged 18 years or older and had complete resection of stage IIIA (lymph node metastases >1 mm), IIIB, or IIIC cutaneous melanoma as per American Joint Committee on Cancer 7th edition criteria, with BRAFV600E or BRAFV600K mutations, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (1:1) via an interactive voice response system, stratified by mutation type and disease stage, to receive oral dabrafenib (150 mg twice daily) plus oral trametinib (2 mg once daily) or matching placebos for 12 months. Patients, physicians, and the investigators who analysed the data were masked to treatment allocation. The primary endpoint was relapse-free survival, reported elsewhere. Health-related quality of life, reported here, was a prespecified exploratory endpoint, and was assessed with the European Quality of Life 5-Dimensions 3-Levels (EQ-5D-3L) questionnaire in the intention-to-treat population. We used a mixed-model repeated-measures analysis to assess differences in health-related quality of life between groups. This study is registered with ClinicalTrials.gov, number NCT01682083. The trial is ongoing, but is no longer recruiting participants. FINDINGS: Between Jan 31, 2013, and Dec 11, 2014, 870 patients were enrolled and randomly assigned to receive dabrafenib plus trametinib (n=438) or matching placebos (n=432). Data were collected until the data cutoff for analyses of the primary endpoint (June 30, 2017). The median follow-up was 34 months (IQR 28-39) in the dabrafenib plus trametinib group and 33 months (20·5-39) in the placebo group. During the 12-month treatment phase, there were no significant or clinically meaningful changes from baseline between groups in EQ-5D-3L visual analogue scale (EQ-VAS) or utility scores. During treatment, there were no clinically meaningful differences in VAS scores or utility scores in the dabrafenib plus trametinib group between patients who did and did not experience the most common adverse events. During long-term follow-up (range 15-48 months), VAS and utility scores were similar between groups and did not differ from baseline scores. At recurrence, there were significant decreases in VAS scores in both the dabrafenib plus trametinib group (mean change -6·02, SD 20·57; p=0·0032) and the placebo group (-6·84, 20·86; p<0·0001); the mean change in utility score also differed significantly at recurrence for both groups (dabrafenib plus trametinib -0·0626, 0·1911, p<0·0001; placebo -0·0748, 0·2182, p<0·0001). INTERPRETATION: These findings show that dabrafenib plus trametinib did not affect patient-reported outcome scores during or after adjuvant treatment, and suggest that preventing or delaying relapse with adjuvant therapy could be beneficial in this setting. FUNDING: Novartis.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Schadendorf D, Hauschild A, Santinami M, et al. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019. PMID: 30928620. doi:10.1016/S1470-2045(18)30940-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。